Zacks Investment Research cut shares of Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) from a buy rating to a hold rating in a report issued on Tuesday morning.

According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

Other analysts also recently issued research reports about the company. JPMorgan Chase & Co. set a $26.00 price target on Enanta Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, August 9th. Robert W. Baird reiterated an outperform rating and set a $27.00 price target (up previously from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 22nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. Enanta Pharmaceuticals currently has a consensus rating of Hold and a consensus price target of $27.29.

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) opened at 31.29 on Tuesday. Enanta Pharmaceuticals has a one year low of $20.39 and a one year high of $35.06. The company has a market capitalization of $595.61 million, a P/E ratio of 27.69 and a beta of 0.61. The stock has a 50 day moving average price of $26.43 and a 200-day moving average price of $24.25.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 21st. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.05. The company earned $12.80 million during the quarter, compared to the consensus estimate of $13.56 million. Enanta Pharmaceuticals had a return on equity of 8.10% and a net margin of 24.55%. The firm’s revenue was down 11.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.29 EPS. Equities research analysts predict that Enanta Pharmaceuticals will post $1.08 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2016/11/30/enanta-pharmaceuticals-inc-enta-downgraded-by-zacks-investment-research-to-hold-2.html.

A number of hedge funds have recently made changes to their positions in the stock. Great Point Partners LLC acquired a new stake in shares of Enanta Pharmaceuticals during the third quarter valued at $21,022,000. Fiera Capital Corp acquired a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at $12,480,000. Matarin Capital Management LLC acquired a new stake in shares of Enanta Pharmaceuticals during the third quarter valued at $6,569,000. Candriam Luxembourg S.C.A. acquired a new stake in shares of Enanta Pharmaceuticals during the third quarter valued at $6,440,000. Finally, Spark Investment Management LLC increased its stake in shares of Enanta Pharmaceuticals by 302.6% in the second quarter. Spark Investment Management LLC now owns 293,100 shares of the company’s stock valued at $6,462,000 after buying an additional 220,300 shares during the last quarter. Hedge funds and other institutional investors own 68.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

5 Day Chart for NASDAQ:ENTA

Receive News & Stock Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.